Fluoxetine-Conjugated Platinum(IV) Prodrugs Targeting eEF2K and Conquering Multidrug Resistance against Triple-Negative Breast Cancer
Journal of Medicinal Chemistry · 08.05.2025 · 68 (9) · 9661-9680
DOI: 10.1021/acs.jmedchem.5c00352 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 23.04.2025. Verfasst von Jia-Qian Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Biology and Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Ph…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Prodrugs, Elongation Factor 2 Kinase, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Applied Basic Research Multi-investment Foundation of Tianjin.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) poses formidable challenges in the clinic owing to its particularly malignant and aggressive properties. Overexpression of eukaryotic elongation factor-2 kinase (eEF2K) is highly correlated with the poor prognosis of TNBC, representing a promising therapeutic target. Herein, Fluoxetine as eEF2K-inhibitor and chemosensitizer was conjugated with cisplatin/oxaliplatin to present two-in-one prodrugs 8-19. Multievaluation indicated that monosubstituted 8 and disubstituted 12 exhibited 407- and 174-fold higher cytotoxicity than cisplatin against MDA-MB-231 cells by elevating DNA damage-induced apoptosis and eEF2K-triggered autophagy. Moreover, 8 and 12 significantly overcame chemoresistance in A549cisR cells, evidenced by downregulating resistance-related key proteins P-gp, GST-π, ATM, and RAD51. Syngeneic and xenograft mouse models demonstrated that 8 and 12 could effectively inhibit tumor growth and metastasis, and reduce toxicity compared to cisplatin in vivo. Additionally, 8 and 12 stimulated immunomodulation including T-cell proliferation and Th1 cytokine production. All results hold the promise of 8 and 12 as multifunctional chemotherapeutic agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemical Biology and Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China.
- National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Insti…
ORCID-Profile: Cheng-Zhi Xie, Xin Qiao, Jing-Yuan Xu
Förderung
- National Natural Science Foundation of China
- Applied Basic Research Multi-investment Foundation of Tianjin
Zitieren
APA
Wang, J. Q., Liu, X. M., Zhu, Z. S., Li, Z., Xie, C. Z., Qiao, X., Feng, Y. K., & Xu, J. Y. (2025). Fluoxetine-Conjugated Platinum(IV) Prodrugs Targeting eEF2K and Conquering Multidrug Resistance against Triple-Negative Breast Cancer. Journal of Medicinal Chemistry, 68(9), 9661-9680. https://doi.org/10.1021/acs.jmedchem.5c00352
Vancouver
Wang JQ, Liu XM, Zhu ZS, Li Z, Xie CZ, Qiao X, et al. Fluoxetine-Conjugated Platinum(IV) Prodrugs Targeting eEF2K and Conquering Multidrug Resistance against Triple-Negative Breast Cancer. Journal of Medicinal Chemistry. 2025;68(9):9661-9680. doi:10.1021/acs.jmedchem.5c00352
BibTeX
@article{Wang2025,
author = {Wang, Jia-Qian and Liu, Xiao-Meng and Zhu, Zi-Shuo and Li, Zhe and Xie, Cheng-Zhi and Qiao, Xin and Feng, Yu-Kuan and Xu, Jing-Yuan},
title = {Fluoxetine-Conjugated Platinum(IV) Prodrugs Targeting eEF2K and Conquering Multidrug Resistance against Triple-Negative Breast Cancer},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {9},
pages = {9661--9680},
doi = {10.1021/acs.jmedchem.5c00352}
}
EUVIMED